BioStock: Evaxion unveils refined business strategy

With a newly appointed CEO, Evaxion Biotech is putting more focus on execution and value realisation through partnerships involving its AI-Immunology platform. BioStock spoke with Evaxion’s CEO Christian Kanstrup about the steps already taken to implement this new strategy and what we can expect from Evaxion in 2024.

Read the interview with Christian Kanstrup at biostock.se:

Evaxion unveils refined business strategy - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/